GE Healthcare Life Sciences Speeding Up High Content Analysis
Boston, MA – August 06, 2007 – GE Healthcare announced today, at the 12th Annual World Congress of Drug Discovery and Development of Innovative Therapeutics, the release of a new IN Cell Investigator software for high content analysis and screening. The IN Cell Investigator 1.3 . offers a comprehensive solution for automated analysis of live and fixed cell assays. It combines Spotfire™ DecisionSite™ visual analytics software with the award-winning IN Cell Developer toolbox and validated IN Cell Analysis modules.
“This software release and the new environmental control module for the IN Cell Analyzer 1000 are part of our continued efforts to deliver more value to the high content analysis community,” said Ger Brophy, general manager of GE Healthare’s Advanced Systems business. “By enabling the analysis of moving cells, IN Cell Investigator helps scientists get more relevant information from living cells for better decision making.”
This software adds new, powerful tools for cell tracking and sub-population analysis to enable more discoveries in high content analysis. It utilizes multi-processor computing to speed up overall analysis and the cell-tracking feature allows scientists to measure changes in cellular movements in response to treatment.
The subpopulation analysis tools enable classification of cells in a wide variety of applications, like apoptosis or cell cycle analysis. Classification and cell tracking can be combined to monitor phenotype changes in individual cells over time, which can be used in RNAi screens or calcium imaging.
“The ready-to-go algorithms for IN Cell [Analyzer] are by far the easiest to use, and the most intuitive that I have tried” said Anthony Davies, Ph.D. from Institute of Molecular Medicine at the St. James Hospital in Dublin. “This has been very important to us, in a multi-user facility, to get projects up and running quickly and to maintain productivity, especially with our relatively high turnover.”
For more detailed information on the IN Cell suite, visit http://www.gelifesciences.com/incell.
Spotfire and DecisionSite are trademarks or registered trademarks of Spotfire, Inc., except in the European Community where Spotfire and DecisionSite are trademarks of Spotfire AB. Other company or product names may be the trademarks of their respective owners.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
